Healthcare -
Biotechnology - NASDAQ - US
$ 8.01
-4.19 %
$ 111 M
Market Cap
17.8
P/E
1. INTRINSIC VALUE
Balance Sheet
Champions Oncology, Inc.
| Current Assets | 13.6 M |
| Cash & Short-Term Investments | 2.62 M |
| Receivables | 9.53 M |
| Other Current Assets | 1.5 M |
| Non-Current Assets | 12.5 M |
| Long-Term Investments | 0 |
| PP&E | 12 M |
| Other Non-Current Assets | 520 K |
| Current Liabilities | 21.5 M |
| Accounts Payable | 5.8 M |
| Short-Term Debt | 1.34 M |
| Other Current Liabilities | 14.4 M |
| Non-Current Liabilities | 6.49 M |
| Long-Term Debt | 6.09 M |
| Other Non-Current Liabilities | 401 K |
EFFICIENCY
Earnings Waterfall
Champions Oncology, Inc.
| Revenue | 50.2 M |
| Cost Of Revenue | 29.4 M |
| Gross Profit | 20.8 M |
| Operating Expenses | 28.1 M |
| Operating Income | -7.36 M |
| Other Expenses | -80 K |
| Net Income | -7.28 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Champions Oncology, Inc.
| Net Income | -7.28 M |
| Depreciation & Amortization | 1.87 M |
| Capital Expenditures | -836 K |
| Stock-Based Compensation | 1.12 M |
| Change in Working Capital | -3.82 M |
| Others | -320 K |
| Free Cash Flow | -6.97 M |
Wall Street Analysts Price Targets
Champions Oncology, Inc.
Wall Street analysts predict an average 1-year price target for CSBR of $12 , with forecasts ranging from
a
low of
$12 to a high of $12 .
CSBR Lowest Price Target
Wall Street Target
12 USD
49.81%
CSBR Average Price Target
Wall Street Target
12 USD
49.81%
CSBR Highest Price Target
Wall Street Target
12 USD
49.81%
4. DIVIDEND
ANALYSIS
CSBR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Champions Oncology, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
accessnewswire.com
- 1 week ago
Champions Oncology Announces Appointment of New CEO
HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, today announced that its Board of Directors has appointed Rob Brainin as Chief Executive Officer and member of the Board of Directors, effective August 25, 2025. Rob, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017.
accessnewswire.com
- 1 week ago
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.
accessnewswire.com
- 3 weeks ago
Champions Oncology: Biological IP Is The Real Asset - Not Preclinical Services
Champions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its evolving business model and scalable, defensible oncology data assets in its current valuation. CSBR's unique, clinically-annotated PDX dataset and early AI/data licensing deals offer significant future upside as the business scales.
seekingalpha.com
- 1 month ago
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
accessnewswire.com
- 3 months ago
Champions Oncology, Inc. (CSBR) Q3 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan - GeoInvesting George Marema - Pareto Ventures Operator Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions].
seekingalpha.com
- 4 months ago
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million
HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2025, ended January 31, 2025. Third Quarter and Recent Highlights: Total revenue increased 42% to $17.0 million Gross profit of $10.4 million; gross margin of 61% Net income of approximately $4.5 million Adjusted EBITDA of $5.2 million Signed first data licensing deal worth up to $8.0 million Hired Matt Newman, Executive Vice President and General Manager, to lead and expand the development of Champions' data licensing platform Year to Date Highlights: Total revenue increased 23% to $44.6 million Gross profit of $23.5 million; gross margin of 53% Net income of $6.5 million Adjusted EBITDA of $8.3 million Ronnie Morris, CEO of Champions, commented, "Our third quarter was transformational, marked by our first major data licensing agreement-an important milestone toward monetizing our proprietary data platform.
accessnewswire.com
- 4 months ago
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2025, on Tuesday, March 11, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
accessnewswire.com
- 4 months ago
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the acceptance of seventeen abstracts for presentation at the AACR Annual Meeting, in Chicago, IL (April 25-30, 2025). These presentations will highlight Champions' cutting-edge research, featuring innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing, as well as AI-driven models that utilize multi-omics datasets to predict patient outcomes.
accessnewswire.com
- 5 months ago
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to announce significant advancements in its bioanalytical services portfolio, specifically, expanding its capabilities with the integration of multiple global Cytek Aurora flow cytometers and the appointment of Troy Tremaine, MBA, to spearhead Bioanalytical Commercial Strategy. The addition of Cytek Aurora instruments elevates Champions' service offerings, building on its already competitive spectral and conventional flow cytometry capabilities.
accesswire.com
- 6 months ago
Champions Oncology: Right Point To Own In The Cycle Thanks To Operating Efficiencies
Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Management has embarked on a one-way journey to reduce working capital and grow the business with zero incremental capital. This has succeeded and the business is now in a prime position to grow sales at 10% CAGR to CY'26 in my opinion.
seekingalpha.com
- 7 months ago
Champions Oncology, Inc. (CSBR) Q2 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2024 Earnings Conference Call December 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Operator Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call.
seekingalpha.com
- 7 months ago
8. Profile
Summary
Champions Oncology, Inc. CSBR
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 111 M
Dividend Yield
0.00%
Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Contact
One University Plaza, Hackensack, NJ, 07601
https://www.championsoncology.com
IPO
Date
Feb. 2, 2007
Employees
210
Officers
Mr. David Barry Miller M.B.A.
Chief Financial Officer
Dr. Maria Mancini Ph.D.
Chief Operating Officer
Ms. Rachel A. Bunting M.B.A., M.S., MBA, MS
Vice President of Global Marketing
Dr. Marianna Zipeto Ph.D.
Executive Vice President of Commercial, Research Services & Partnering
Dr. Ronnie Morris M.D.
Chief Executive Officer & Director
Dr. Michael Ritchie M.B.A., Ph.D.
Chief Commercial Officer